Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...

Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

While consumer spending is high, so is business investment, according to  Deloitte  ? which can make differentiating amongst competitors harder than ever with significant gains or losses at ...

Vantage Foundation proudly announces its partnership with SOS Children's Villages Philippines, a NGO committed to providing ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on TikTok.

Biogen meanwhile is also pursuing other avenues of RNA drug discovery and development, and in 2018 expanded the partnership with Ionis Pharma which delivered Spinraza to the market, paying $350 ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.